This week ’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy
Last weekend, the Senate passed theInflation Reduction Act which includes dangerous price-setting provisions. The bill now heads to the House for consideration, where it is not too late for them to stand up for patients and medical innovation by opposing the bill. (Source: The Catalyst)
Source: The Catalyst - August 10, 2022 Category: Pharmaceuticals Tags: Research and Development Patients Government Price Setting Source Type: news

Value assessment should include all aspects of value that matter to patients
We need to move toward a more value-driven health care system that centers around patients ’ needs. Sound evidence can help guide us toward that, and we’re committed to developing tools to help patients, physicians and others make informed decisions. (Source: The Catalyst)
Source: The Catalyst - August 10, 2022 Category: Pharmaceuticals Authors: Emilie Signora Tags: Value Assessment Source Type: news

Making coupons count for patients with HIV
Despite having insurance, too many patients with HIV face high out-of-pocket costs for brand medicines. This is largely driven by insurer-imposed barriers that shift the cost of life-saving care onto patients. (Source: The Catalyst)
Source: The Catalyst - August 8, 2022 Category: Pharmaceuticals Authors: Emilie Signora Tags: Health Insurance HIV/AIDS Patient Assistance Programs Out-of-Pocket Costs Source Type: news

Myth vs. Fact: The Senate ’s latest price setting proposal
The narratives being built around the Senate ’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t the facts. Here, we bust those myths. (Source: The Catalyst)
Source: The Catalyst - August 5, 2022 Category: Pharmaceuticals Tags: Research and Development Patients Medicare Policy Solutions Government Price Setting Source Type: news

An open letter to Congress: Stand with patients and future cures
I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon theirlatest drug pricing proposal. You can read the letterhere or below: (Source: The Catalyst)
Source: The Catalyst - August 4, 2022 Category: Pharmaceuticals Tags: Research and Development PhRMA Member Company Government Price Setting Source Type: news

ICYMI: Patients across the country are sharing concerns about government price setting
As members of Congress continue to push forward misguided government price-setting policies under the guise of “negotiation,” patient advocates across the country have been speaking out in local media outlets about the potential consequences. (Source: The Catalyst)
Source: The Catalyst - August 3, 2022 Category: Pharmaceuticals Authors: Matthew Norawong Tags: Patients Voters for Cures Government Price Setting Source Type: news

The Senate ’s latest price setting proposal will undermine U.S. economic growth
Last week, we examined ways the latest drug pricing proposal will underminepatient access to medicines,American medical innovation andour health care system as a whole. But there is another consequence that we can ’t leave out: the impact this proposal will have on the biopharmaceutical industry’s contributions to American jobs and the economy. (Source: The Catalyst)
Source: The Catalyst - August 3, 2022 Category: Pharmaceuticals Tags: Research and Development Economic Impact Medicare Policy Solutions Government Price Setting Source Type: news

Celebrating Medicare ’s 57th anniversary
In case you missed it, Saturday, July 30, marked the anniversary of Medicare. For 57 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans with certain medical needs. To celebrate, we are reflecting on the history of the program that benefits more than 60 million Americans. Unfortunately, some members of Congress are considering significant changes to Medicare that could have adevastating effect on millions of Americans. (Source: The Catalyst)
Source: The Catalyst - August 2, 2022 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Medicare Policy Solutions Government Price Setting Source Type: news

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
Anew analysis by the health care analytics and research firm Avalere reveals the partisan drug pricing bill will have a much deeper impact on the biopharmaceutical research industry than previously reported. (Source: The Catalyst)
Source: The Catalyst - August 1, 2022 Category: Pharmaceuticals Authors: Brian Newell Tags: Research and Development Patients Policy Solutions Government Price Setting Source Type: news

ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
During a widely attended media briefing, physicians, biopharmaceutical leaders, and a brave cancer survivor, all expressed their strong opposition to the extreme drug pricing bill Congress is currently considering. They explained why allowing the government to set the price for lifesaving medicines will decimate the hope of curing cancer and other deadly diseases and why policymakers should start over with a new bipartisan approach that lowers costs and protects future innovation. (Source: The Catalyst)
Source: The Catalyst - July 29, 2022 Category: Pharmaceuticals Authors: Brian Newell Tags: Research and Development Economic Impact Patients Government Price Setting Source Type: news

The Senate ’s latest price setting proposal will undermine: Our health care system
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting and, if implemented, would require the government to dictate prices and choose winners and losers when it comes to which diseases are likely to see new treatments. Instead of addressing a broken insurance system, the most recent proposal doubles down on bad policies that will threaten patient access to medicines and future innovations. This is the final blog in a three-part series where we discuss the very real threats of the ...
Source: The Catalyst - July 28, 2022 Category: Pharmaceuticals Tags: Medicare Out-of-Pocket Costs Policy Solutions Government Price Setting Source Type: news

The Senate ’s latest price setting proposal will undermine: American medical innovation
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting and, if implemented, would require the government to dictate prices and choose winners and losers when it comes to which diseases are likely to see new treatments. Instead of addressing a broken insurance system, the most recent proposal doubles down on bad policies that will threaten patient access to medicines and future innovations. This is the second blog in a three-part series where we discuss the very real threats of the...
Source: The Catalyst - July 27, 2022 Category: Pharmaceuticals Tags: Research and Development Policy Solutions Government Price Setting Source Type: news

The Senate ’s latest price setting proposal will undermine: Patient access to medicines
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting and, if implemented, would require the government to dictate prices and choose winners and losers when it comes to which diseases are likely to see new treatments. Instead of addressing a broken insurance system, the most recent proposal doubles down on bad policies that will threaten patient access to medicines and future innovations. This is the first blog in a three-part series where we discuss the very real threats of the ...
Source: The Catalyst - July 26, 2022 Category: Pharmaceuticals Tags: Part D Out-of-Pocket Costs Part B Policy Solutions Government Price Setting Source Type: news

Patent policy changes proposed by USPTO and FDA would leave patients behind
Kathi Vidal, Director of the USPTO, and Robert M. Califf, FDA Commissioner, recently outlined several policy areas where they plan to collaborate on addressing drug pricing. PhRMA supports the goal of improving health care affordability for Americans, but we disagree that changes are needed to U.S. patent law and policy to increase generic and biosimilar competition. (Source: The Catalyst)
Source: The Catalyst - July 22, 2022 Category: Pharmaceuticals Authors: Megan Van Etten Tags: Patents Intellectual Property Source Type: news

The Patient Perspective: Government price-setting harms patients
Unfortunately, policymakers are again looking for bumper-sticker answers to the health care affordability challenges many Americans face, ignoring real commonsense solutions in exchange for flawed government “negotiation” schemes. The current misguided drug pricing plan included in the reconciliation package mandates the government set prices for medicines – a plan that will completely upend our competitive ecosystem in the United States and threaten access to new medicines. (Source: The Catalyst)
Source: The Catalyst - July 22, 2022 Category: Pharmaceuticals Tags: Patients Policy Solutions Voters for Cures Government Price Setting Source Type: news